Jul 15, 2019 / 08:45PM GMT
Operator
Good day, ladies and gentlemen, and welcome to the Arbutus Biopharma Corporation conference call. (Operator Instructions) As a reminder, this call will be recorded. I would now like to introduce your host for today's conference. Ms. Pam Murphy, you may begin.
Pam Murphy - Arbutus Biopharma Corporation - IR Consultant
Good afternoon. On the call from the Arbutus Executive Team are Bill Collier, President and Chief Executive Officer; Dr. Gaston Picchio, Chief Development Officer; Dr. Mike Sofia, Chief Scientific Officer; and David Hastings, Chief Financial Officer. Bill will begin with a few opening remarks followed by Gaston, who will discuss the preliminary Phase Ia/Ib results for AB-506 which has -- which were announced earlier this afternoon. We'll then open up the call for Q&A.
Before we begin, we'd like to remind you that some of the statements made during the call today are forward-looking statements including statements regarding expectations for Arbutus' proprietary HBV pipeline including clinical results and time lines for our 2 lead
Arbutus Biopharma Corp to Discuss Preliminary Phase 1a/1b Clinical Trial Results for AB-506 - Call Transcript
Jul 16, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers